Skip to main content
Top
Published in: Diagnostic Pathology 1/2019

Open Access 01-12-2019 | Lymphoma | Research

Clinicopathological categorization of hydroa vacciniforme-like lymphoproliferative disorder: an analysis of prognostic implications and treatment based on 19 cases

Authors: Na Guo, Yueqiong Chen, Yu Wang, Yuhua Huang, Yanfen Feng, Min Li, Huilan Rao

Published in: Diagnostic Pathology | Issue 1/2019

Login to get access

Abstract

Background

Hydroa vacciniforme-like lymphoproliferative disorder (HV-LPD) is a cutaneous form of chronic active Epstein-Barr virus (EBV) infection, which occurs mainly in children in Latin America and Asia. It can progress to systemic lymphoma. However, prognostic factors and treatment remain unclear.

Methods

This retrospective study reviewed the clinical, morphologic, immunophenotypical features, and clinical treatment of 19 patients with HV-LPD.

Results

All 19 patients had skin lesions in the face, extremities, or areas unexposed to the sun, including edema, blistering, ulceration, and scarring. The course was slowly progressive and relapsing. Histopathology showed an atypical lymphocytic infiltrate in the dermis and/or subcutaneous tissue. The lesions had a cytotoxic T/NK-cell immunophenotype. Among 19 patients, 7 (37%) exhibited CD4+ T cells, 5 (26%) exhibited CD8+ T cells, and 7 (37%) exhibited CD56+ cells. Of 12 cases with a T-cell phenotype, molecular analyses demonstrated that 7 had monoclonal rearrangements in the T-cell receptor genes. Three cases had an NK-cell phenotype and had polyclonal rearrangements in the TCR genes. All cases were associated with EBV infections. Among 19 patients, 9 (47.4%) received chemotherapy. Only one patient received allogeneic transplantation and EBV-specific cytotoxic T lymphocyte treatment after chemotherapy. That patient was the only one alive without disease at the latest follow up. Nine patients died of systemic lymphoma with disease progression, indicating irreversible process.

Conclusions

This study confirmed that HV-LPD is a broad-spectrum EBV+ lymphoproliferative disorder. It progressed to EBV+ systemic T/NK lymphoma, although some patients had a more indolent, chronic course. Cytopenia, elevated lactate dehydrogenase, destructive-multiorgan involvement, and older age were poor prognostic factors. Only allogeneic transplantation was curative.
Literature
1.
go back to reference Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues (IARC WHO classification of tumours) revised 4th edition. Lyon: IARC Press; 2017. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues (IARC WHO classification of tumours) revised 4th edition. Lyon: IARC Press; 2017.
2.
go back to reference Quintanilla-Martinez L, Ridaura C, Nagl F, et al. Hydroa vacciniforme-like lymphoma: a chronic EBV+ lymphoproliferative disorder with risk to develop a systemic lymphoma. Blood. 2013;122(18):3101–10.CrossRef Quintanilla-Martinez L, Ridaura C, Nagl F, et al. Hydroa vacciniforme-like lymphoma: a chronic EBV+ lymphoproliferative disorder with risk to develop a systemic lymphoma. Blood. 2013;122(18):3101–10.CrossRef
3.
go back to reference Jaffe ES, Gru AA. Cutaneous EBV-related lymphoproliferative disorders. Semin Diagn Pathol. 2017;34(1):60–75.CrossRef Jaffe ES, Gru AA. Cutaneous EBV-related lymphoproliferative disorders. Semin Diagn Pathol. 2017;34(1):60–75.CrossRef
4.
go back to reference Swerdlow SH, Campo E, Harris NL, et al. WHO classification of Tumours of Haematopoietic and lymphoid tissues (IARC WHO classification of Tumours). 4th ed. Lyon: IARC Press; 2008. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of Tumours of Haematopoietic and lymphoid tissues (IARC WHO classification of Tumours). 4th ed. Lyon: IARC Press; 2008.
5.
go back to reference Xu Z, Lian S. Epstein-Barr virus-associated hydroa vacciniforme-like cutaneous lymphoma in seven Chinese children. Pediatr Dermatol. 2010;27(5):463–9.CrossRef Xu Z, Lian S. Epstein-Barr virus-associated hydroa vacciniforme-like cutaneous lymphoma in seven Chinese children. Pediatr Dermatol. 2010;27(5):463–9.CrossRef
6.
go back to reference Doeden K, Molina-Kirsch H, Perez E, Warnke R, Sundram U. Hydroa-like lymphoma with CD56 expression. J Cutan Pathol. 2008;35(5):488–94.CrossRef Doeden K, Molina-Kirsch H, Perez E, Warnke R, Sundram U. Hydroa-like lymphoma with CD56 expression. J Cutan Pathol. 2008;35(5):488–94.CrossRef
7.
go back to reference Zhang G, Bai HX, Yang L, et al. Nk-/T-cell lymphoma resembling hydroa vacciniforme with positive CD4 marker expression: a diagnostic difficulty. Am J Dermatopathol. 2013;35(1):94–7.CrossRef Zhang G, Bai HX, Yang L, et al. Nk-/T-cell lymphoma resembling hydroa vacciniforme with positive CD4 marker expression: a diagnostic difficulty. Am J Dermatopathol. 2013;35(1):94–7.CrossRef
8.
go back to reference Cho KH, Lee SH, Kim CW, et al. Epstein-Barr virus-associated lymphoproliferative lesions presenting as a hydroa vacciniforme-like eruption: an analysis of six cases. Br J Dermatol. 2004;151(2):372–80.CrossRef Cho KH, Lee SH, Kim CW, et al. Epstein-Barr virus-associated lymphoproliferative lesions presenting as a hydroa vacciniforme-like eruption: an analysis of six cases. Br J Dermatol. 2004;151(2):372–80.CrossRef
9.
go back to reference Iwatsuki K, Satoh M, Yamamoto T, et al. Pathogenic link between hydroa vacciniforme and Epstein–Barr virusassociated hematologic disorders. Arch Dermatol. 2006;142:587–95.CrossRef Iwatsuki K, Satoh M, Yamamoto T, et al. Pathogenic link between hydroa vacciniforme and Epstein–Barr virusassociated hematologic disorders. Arch Dermatol. 2006;142:587–95.CrossRef
10.
go back to reference Cohen JI, Kimura H, Nakamura S, et al. Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008. Ann Oncol. 2009;20(9):1472–82.CrossRef Cohen JI, Kimura H, Nakamura S, et al. Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008. Ann Oncol. 2009;20(9):1472–82.CrossRef
11.
go back to reference Ohshima K, Kimura H, Yoshino T, et al. Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD. Pathol Int. 2008;58:209–17.CrossRef Ohshima K, Kimura H, Yoshino T, et al. Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD. Pathol Int. 2008;58:209–17.CrossRef
12.
go back to reference Wang L, Wang H, Wang JH, et al. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase. Oncotarget. 2015;6(30):30317–26.PubMedPubMedCentral Wang L, Wang H, Wang JH, et al. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase. Oncotarget. 2015;6(30):30317–26.PubMedPubMedCentral
13.
go back to reference Feng Y, Rao H, Lei Y, et al. CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China. Chin J Cancer. 2017;36:43.CrossRef Feng Y, Rao H, Lei Y, et al. CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China. Chin J Cancer. 2017;36:43.CrossRef
14.
go back to reference Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster group trial NHL-BFM 90. Blood. 1999;94(10):3294–306.PubMed Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster group trial NHL-BFM 90. Blood. 1999;94(10):3294–306.PubMed
15.
go back to reference Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM group study NHL-BFM95. Blood. 2005;105(3):948–58.CrossRef Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM group study NHL-BFM95. Blood. 2005;105(3):948–58.CrossRef
16.
go back to reference Barrionuevo C, Anderson VM, Zevallos-Giampietri E, et al. Hydroa-like cutaneous T-cell lymphoma:a clinicopathologic and molecular genetic study of 16 pediatric cases from Peru. Appl Immunohistochem Mol Morphol. 2002;10:7–14.PubMed Barrionuevo C, Anderson VM, Zevallos-Giampietri E, et al. Hydroa-like cutaneous T-cell lymphoma:a clinicopathologic and molecular genetic study of 16 pediatric cases from Peru. Appl Immunohistochem Mol Morphol. 2002;10:7–14.PubMed
17.
go back to reference Sangueza M, Plaza JA. Hydroa vacciniforme-like cutaneous T-cell lymphoma: clinicopathologic and immunohistochemical study of 12 cases. J Am Acad Dermatol. 2013;69(1):112–9.CrossRef Sangueza M, Plaza JA. Hydroa vacciniforme-like cutaneous T-cell lymphoma: clinicopathologic and immunohistochemical study of 12 cases. J Am Acad Dermatol. 2013;69(1):112–9.CrossRef
18.
go back to reference Qin C, Huang Y, Feng Y, et al. Clinicopathological features and EBV infection status of lymphoma in children and adolescents in South China: a retrospective study of 662 cases. Diagn Pathol. 2018;13:17.CrossRef Qin C, Huang Y, Feng Y, et al. Clinicopathological features and EBV infection status of lymphoma in children and adolescents in South China: a retrospective study of 662 cases. Diagn Pathol. 2018;13:17.CrossRef
19.
go back to reference Rodríguez-Pinilla SM, Barrionuevo C, Garcia J, et al. EBV-associated cutaneous NK/T-cell lymphoma: review of a series of 14 cases from Peru in children and young adults. Am J Surg Pathol. 2010;34(12):1773–82.CrossRef Rodríguez-Pinilla SM, Barrionuevo C, Garcia J, et al. EBV-associated cutaneous NK/T-cell lymphoma: review of a series of 14 cases from Peru in children and young adults. Am J Surg Pathol. 2010;34(12):1773–82.CrossRef
20.
go back to reference Zhang X, Wang T, Wang L. Hydroa vacciniforme-like lymphoma in Tibetan children: 2 cases and a literature review. Am J Dermatopathol. 2018;40(5):358–61.CrossRef Zhang X, Wang T, Wang L. Hydroa vacciniforme-like lymphoma in Tibetan children: 2 cases and a literature review. Am J Dermatopathol. 2018;40(5):358–61.CrossRef
21.
go back to reference Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.CrossRef Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.CrossRef
22.
go back to reference Sundram U. Cutaneous lymphoproliferative disorders: What's new in the revised 4th edition of the World Health Organization (WHO) classification of lymphoid neoplasms. Adv Anat Pathol. 2019;26(2):93–113.CrossRef Sundram U. Cutaneous lymphoproliferative disorders: What's new in the revised 4th edition of the World Health Organization (WHO) classification of lymphoid neoplasms. Adv Anat Pathol. 2019;26(2):93–113.CrossRef
23.
go back to reference Yang YQ, Fan L, Wang L, et al. Systemic lymphoma arising from hydroa vacciniforme-like lymphoma: report of two cases with review of literature. Int J Clin Exp Pathol. 2014;7(9):6403–8.PubMedPubMedCentral Yang YQ, Fan L, Wang L, et al. Systemic lymphoma arising from hydroa vacciniforme-like lymphoma: report of two cases with review of literature. Int J Clin Exp Pathol. 2014;7(9):6403–8.PubMedPubMedCentral
24.
go back to reference Feng S, Jin P, Zeng X. Hydroa vacciniforme-like primary cutaneous CD8-positive T-cell lymphoma. Eur J Dermatol. 2008;18(3):364–5.PubMed Feng S, Jin P, Zeng X. Hydroa vacciniforme-like primary cutaneous CD8-positive T-cell lymphoma. Eur J Dermatol. 2008;18(3):364–5.PubMed
25.
go back to reference Paik JH, Choe JY, Kim H, et al. Clinicopathological categorization of Epstein–Barr virus-positive T/NK-cell lymphoproliferative disease: an analysis of 42 cases with an emphasis on prognostic implications. Leuk Lymphoma. 2017;58(1):53–63.CrossRef Paik JH, Choe JY, Kim H, et al. Clinicopathological categorization of Epstein–Barr virus-positive T/NK-cell lymphoproliferative disease: an analysis of 42 cases with an emphasis on prognostic implications. Leuk Lymphoma. 2017;58(1):53–63.CrossRef
26.
go back to reference Kim YJ, Choi SY, Lee WJ, et al. Two cases of hydroa vacciniforme-like lymphoproliferative disease controlled by anti-inflammatory agents. Photodermatol Photoimmunol Photomed. 2017;33(5):287–90.CrossRef Kim YJ, Choi SY, Lee WJ, et al. Two cases of hydroa vacciniforme-like lymphoproliferative disease controlled by anti-inflammatory agents. Photodermatol Photoimmunol Photomed. 2017;33(5):287–90.CrossRef
27.
go back to reference Sato E, Ohga S, Kuroda H, et al. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan. Am J Hematol. 2008;83:721–7.CrossRef Sato E, Ohga S, Kuroda H, et al. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan. Am J Hematol. 2008;83:721–7.CrossRef
28.
go back to reference Beltran BE, Maza I, Moises-Alfaro CB, et al. Thalidomide for the treatment of hydroa vacciniforme-like lymphoma: report of four pediatric cases from Peru. Am J Hematol. 2014;89(12):1160–1.CrossRef Beltran BE, Maza I, Moises-Alfaro CB, et al. Thalidomide for the treatment of hydroa vacciniforme-like lymphoma: report of four pediatric cases from Peru. Am J Hematol. 2014;89(12):1160–1.CrossRef
29.
go back to reference El-Mallawany NK, Geller L, Bollard CM, et al. Long-term remission in a child with refractory EBV(+) hydroa vacciniforme-like T-cell lymphoma through sequential matched EBV(+)-related allogeneic hematopoietic SCT followed by donor-derived EBV-specific cytotoxic T-lymphocyte immunotherapy. Bone Marrow Transplant. 2011;46(5):759–61.CrossRef El-Mallawany NK, Geller L, Bollard CM, et al. Long-term remission in a child with refractory EBV(+) hydroa vacciniforme-like T-cell lymphoma through sequential matched EBV(+)-related allogeneic hematopoietic SCT followed by donor-derived EBV-specific cytotoxic T-lymphocyte immunotherapy. Bone Marrow Transplant. 2011;46(5):759–61.CrossRef
30.
go back to reference Sawada A, Inoue M, Kawa K. How we treat chronic active Epstein-Barr virus infection. Int J Hematol. 2017;105(4):406–18.CrossRef Sawada A, Inoue M, Kawa K. How we treat chronic active Epstein-Barr virus infection. Int J Hematol. 2017;105(4):406–18.CrossRef
Metadata
Title
Clinicopathological categorization of hydroa vacciniforme-like lymphoproliferative disorder: an analysis of prognostic implications and treatment based on 19 cases
Authors
Na Guo
Yueqiong Chen
Yu Wang
Yuhua Huang
Yanfen Feng
Min Li
Huilan Rao
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2019
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/s13000-019-0859-4

Other articles of this Issue 1/2019

Diagnostic Pathology 1/2019 Go to the issue